Indian version of Inavolisib price and buying guide

As of now (January 2026), the generic or original version of Inavolisib (Inavolisib) has not yet been launched in the Indian market, and the cost of treatment with Inavolisib is still high. For patients who need this medication, the Indian version of Inarisep is not on the market, so patients cannot purchase generic versions of Inarisep in India.

In other countries, the originator drug of inariside has been approved and widely used. Taking the domestic market as an example, Inavolisib (trade name: Inavolisib) has been officially launched in May 2020 and has been included in the national medical insurance reimbursement catalog. Common specifications include 3mg 7 tablets and 4 tablets and 9mg 7 tablets and 4 tablets. The price is about 30,000 yuan. The specific price may be affected by different regions and medical insurance policies. When purchasing, patients can consult local hospitals or pharmacies for specific drug prices and medical insurance reimbursement policies.

The price of inarisep in overseas markets is relatively high, especially in developed countries such as Europe and the United States, where the price of the original drug usually reaches more than 200,000 yuan per box. Prices will vary due to exchange rate fluctuations and drug pricing strategies in different regions. If patients need to purchase the drug overseas, it is recommended to go through formal channels, such as hospitals or authorized pharmacies, to ensure that the source of the drug is legal and reliable.

Currently, there is no generic version of Inariside available in India. Although India is known for its low drug prices, the price of Inaliset has not dropped significantly due to the launch of generic drugs. In the future, as the patent of inarisep expires, generic versions may appear, which will help reduce the price of the drug and improve accessibility to more patients.

In general, as a newPI3Kα inhibitor, inaliset has outstanding therapeutic effects in the treatment of breast cancer, but the high price is still the main obstacle faced by patients. As more countries approve marketing and medical insurance policies gradually improve, the accessibility of inarisep is expected to be further improved in the future.

Reference materials:https://www.itovebi-hcp.com/